FDA warns Olympus over quality-system failures across six medical device plants, including unvalidated designs and released nonconforming devices.
What happened
FDA inspected six Olympus medical device facilities between Oct. 6 and Nov. 21, 2025 and issued Form FDA 483 inspection observations at each. FDA found the devices were adulterated (legally defective under the Act) because methods, facilities, or controls did not meet current good manufacturing practice (CGMP) requirements in the Quality System regulation, and nonconforming devices were distributed with significant patient risks. Olympus responded to the 483s, but FDA said the adequacy of many responses cannot be determined.
What FDA found
At Shirakawa, Olympus did not identify or control catastrophic UHI-4 insufflator hazards such as air embolism, arrhythmia, and death, and did not validate the design under actual or worst-case use after a patient death and Class I recall.
21 CFR 820.30(g)At Aomori, Olympus did not assess known Sphincterotome hazards, including unintended blood-vessel cutting and failure of automated inspection to catch burrs and flakes, and did not set risk controls for wire manufacturing.
21 CFR 820.30(g)At Hamburg and Hachioji, Olympus sold cystoscopes and bronchoscopes with instructions claiming laser compatibility without validating use with those lasers, leading to recalls for sheath damage/tissue injury and endobronchial combustion risk.
21 CFR 820.30(g)At Brooklyn Park, Olympus reworked and released nonconforming Vizishot 2 FLEX devices without adequate justification and changed the manufacturing date to get around a ship hold.
21 CFR 820.90(a)At Brooklyn Park and Hinode, Olympus did not fully control nonconforming Shockpulse generators, MAJ-210 biopsy valves that failed durability testing, and devices with sterile-barrier seal overlap defects.
21 CFR 820.90(a)At Brooklyn Park, Olympus did not validate heat-sealing processes used to make sterile packages, including challenge conditions, a decommissioned sealer, and unvalidated setpoints.
21 CFR 820.75(a)
What FDA wants
FDA tells Olympus to correct the violations and provide objective evidence that corrections are complete and effective; the provided text does not state a response deadline.
Who should pay attention
- hospitals and surgical teams using Olympus endoscopes and surgical devices
- companies that buy or distribute medical devices from global manufacturers
- quality teams at device makers with multiple manufacturing sites
This is a summary. Read the original letter on fda.gov.